Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

NCT03913143 is registered in ClinicalTrials.gov with ProQR Therapeutics as lead sponsor.

NCT NCT03913143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Lead sponsor
ProQR Therapeutics
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 4, 2019
Completion date
March 31, 2023
Enrollment
36 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

blindness, eye diseases, eye diseases, hereditary, eye disorders congenital, leber congenital amaurosis, leber congenital amaurosis 10, neurologic manifestations, retinal disease, sensation disorders, vision disorders